Cajal Neuroscience

About

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Seattle,Washington,United States
101 - 250
https://cajalneuro.com

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $96M
Industries: Biotechnology,Neuroscience,Pharmaceutical,Therapeutics
Founded date: Jan 1, 2020
Number Of Employee: 101 - 250
Operating Status: Active

Cajal Neuroscience is a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. The company combines a suite of state-of-the-art approaches and technologies, including integrative human genetics and multi-omics, high-throughput functional genomics, and advanced microscopy, to accelerate neurodegeneration target and drug discovery.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

$96M

Cajal Neuroscience has raised a total of $96M in funding over 2 rounds. Their latest funding was raised on Nov 29, 2022 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 29, 2022	Series A	$96M	7	Lux Capital The Column Group	—	Detail
Jan 1, 2020	Seed	—	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

7

Cajal Neuroscience is funded by 7 investors. Lux Capital and The Column Group are the most recent investors.

Investor Name	Lead Investor	Funding Round
Lux Capital	Yes	Series A
The Column Group	Yes	Series A
Alexandria Venture Investments	—	Series A
Bristol Myers Squibb	—	Series A
Dolby Family Ventures	—	Series A
Evotec	—	Series A
Two Sigma Ventures	—	Series A